Mounjaro
by Eli Lilly · DCGI approved March 2025 (DCGI/CDSCO marketing authorisation)
| Active ingredient | Tirzepatide (Dual GIP and GLP-1 receptor agonist) |
| Indication | Type 2 Diabetes + Obesity |
| Manufacturer | Eli Lilly and Company |
| DCGI status | Approved March 2025 (DCGI/CDSCO marketing authorisation) |
| Price (MRP) | ₹14,000–27,500/month Premium pricing reflects patent-protected status. No generic tirzepatide is expected in India before approximately 2036. |
| Format | Prefilled KwikPen (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly) · Single-dose vial |
| Prescription | Schedule H — required |
How Mounjaro compares
Mounjaro is Eli Lilly's brand of tirzepatide — a different molecule from semaglutide that activates both GIP and GLP-1 receptors. The SURMOUNT-1 trial showed approximately 22% mean weight loss versus semaglutide's 15.3% in STEP 1, and the SURMOUNT-5 head-to-head suggests tirzepatide produces greater weight loss. DCGI approved Mounjaro in March 2025 for both type 2 diabetes and obesity. Premium pricing reflects patent protection — no Indian generic tirzepatide is expected before approximately 2036.
About Eli Lilly
Eli Lilly is the manufacturer behind Mounjaro and Zepbound. Mounjaro became India's top-selling drug by value in October 2025, generating ₹333 crore in cumulative sales since its March 2025 launch — one of the fastest scale-ups for any new injectable antidiabetic in India. Lilly's pipeline includes additional dual and triple agonist obesity drugs.
Manufacturer announcement
Additional source
Reuters / Yahoo Finance — Mounjaro India launchGLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.